evaluable population. F: Scatterplot of change in A1C vs. change in body weight. * P/H110210.05 versus exenatide BID 3exenatide QW. BL, baseline.Exenatide once weekly, 52-week safety and efÔ¨Åcacy 1258 DIABETES CARE,VOLUME 33, NUMBER 6, J UNE2010 care.diabetesjournals.orgDownloaded from http://diabetesjournals.org/care/article-pdf/33/6/1255/605969/zdc0061000 255.pdf by guest on 17 January 2024